VOA慢速英语20060201a

（单词翻译）

HEALTH REPORT - Once-Daily Pill Could Simplify H.I.V. Treatment By Cynthia Kirk

Broadcast: Wednesday, February 01, 2006

I'm Steve Ember with the VOA Special English Health Report.

Sometimes the best medicine is more than one kind of medicine. Malaria¹, tuberculosis² and H.I.V./AIDS, for example, are all treated with combinations of drugs.


Myers Squibb and Gilead Sciences have combined many H.I.V. drugs into a single pill

But that can mean a lot of pills to take. It would be simpler if drug companies combined all the medicines into a single pill, taken just once a day.

Now, two companies say they have done that for people just starting treatment for H.I.V., the virus that causes AIDS. The companies are Bristol-Myers Squibb and Gilead Sciences.

They have developed a single pill that combines three drugs currently on the market. Bristol-Myers Squibb sells one of them under the name Sustiva. Gilead combined the others, Emtriva and Viread, into a single pill in two thousand four.

Combining drugs involves more than technical issues. It also involves issues of competition if the drugs are made by different companies. The new once-daily pill is the result of what is described as the first joint³ venture agreement of its kind in the treatment of H.I.V.

In January the New England Journal of Medicine published a study of the new pill. Researchers compared its effectiveness to that of the widely used combination of Sustiva and Combivir. Combivir contains two drugs, AZT and 3TC. The researchers say that after one year of treatment, the new pill suppressed H.I.V. levels in more patients and with fewer side effects.

Gilead paid for the study. Professor Joel Gallant⁴ at the Johns Hopkins School of Medicine in Baltimore, Maryland, led the research. He is a paid adviser⁵ to Gilead and Bristol-Meyers Squibb as well as the maker⁶ of Combivir, GlaxoSmithKline.

GlaxoSmithKline reacted to the findings by saying that a single study is of limited value. It says the effectiveness of Combivir has been shown in each of more than fifty studies.

The price of the new once-daily pill has not been announced. But Gilead and Bristol-Myers Squibb say they will provide it at reduced cost to developing countries.

They plan in the next few months to ask the United States Food and Drug Administration to approve the new pill.

There are limits to who could take it because of the different drugs it contains. For example, pregnant women are told not to take Sustiva because of the risk of birth disorders⁷.

Experts say more than forty million people around the world are living with H.I.V.

This VOA Special English Health Report was written by Cynthia Kirk. Read and listen to our reports at www.unsv.com. I'm Steve Ember.